C
Coya Therapeutics
Leveraging proprietary regulatory T cells (Tregs) and exosome platforms to address neurologic and autoimmune disorders
About Coya Therapeutics
Coya Therapeutics is a clinical-stage biotechnology company that focuses on developing proprietary therapies aimed at enhancing the function of regulatory T cells (Tregs). These therapies are designed to address neurodegenerative, autoimmune, and metabolic diseases, which are areas with significant unmet medical needs. The company operates in the biotechnology sector, targeting healthcare providers and patients who suffer from these chronic conditions. Coya Therapeutics' business model revolves around research and development, clinical trials, and eventual commercialization of their therapeutic products. Revenue generation is anticipated through the successful approval and market launch of their therapies, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2020
- Headquarters
- Houston, United States
- Listing
- IPO 2023
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 79.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VC✓Other financing | Jan 2026 | $11M | — | Greenlight Capital · Dr. Reddy’s Laboratories | ↗ |
| POST IPO EQUITY✓Other financing | Oct 2025 | $20M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Coya Therapeutics is 9K monthly website visits, up 172.7% over the last three months. Coya Therapeutics's team grew 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Coya Therapeutics in the Houston ecosystem
The Coya Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Allele Capital Partners
Series B and later1 investor entered at this stage
Alzheimer's Drug Discovery Foundation
Other known investors5 additional known investors
Dr. Reddy’s Laboratories- GCGreenlight Capital
Houston Methodist
Checkmate Capital- CGCheckmate Capital Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Coya Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Coya Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










